Sequence-dependent administration of raloxifene and 5-fluorouracil/ pemetrexed protects against pemetrexed cytotoxicity in human bone marrow

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 825-833

  Das, Jharna R ^a   Fryar Tita, Elizabeth B ^b   Green, Sidney ^a   Southerland, William M ^a   Bowen, Donnell ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

5 fluorouracil; Dihydrofolate reductase; Multitargeted antifolate; Pemetrexed; Raloxifene; Thymidylate synthase

Indexed keywords

DIHYDROFOLATE REDUCTASE; FLUOROURACIL; FOLIC ACID ANTAGONIST; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; RALOXIFENE; RETINOBLASTOMA PROTEIN; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; BONE MARROW TOXICITY; BREAST CANCER; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL PROTECTION; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE SEQUENCE; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; MONOTHERAPY; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW CELLS; BONE MARROW DISEASES; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; RALOXIFENE;

EID: 34247132691     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bertino JR: Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 11: 5-14, 1993.
2. Bailey LB and Gregory JF 3rd: Folate metabolism and requirements. J Nutr 129: 779-782, 1999.
3. Taylor EC and Patel HH: Synthesis of pyrazolo(3,4,-d) pyrimidine analogues of the potent antitumor agent n-[4-(2-[2-amino-3,4-dihydro-4-oxo-7H- pyrrolo(2,3-d)pyrimidin-5-yl]ethyl)benzoyl]-L-glutamic acid (LY231514). Tetrahedron Lett 48: 8089-8100, 1992.
4. Alimta® (pemetrexed) [product information]. Indianapolis, Ind: Eli Lilly and Company, 2004.
5. Rollins KD and Lindley C: Pemetrexed: a multitargeted antifolate. Clin Ther 27: 1343-1382, 2005.
6. Taylor EC and Liu B: A new route to 7-substituted derivatives of n-[4-(2-[2-amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimidin-5-yl]ethyl) benzoyl]-L-glutamic acid [ALIMTA (LY231514, MTA)]. J Org Chem 66: 3726-3738, 2001.
7. Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin MB, Wilke H and Seeber S: Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 15: 389-400, 1997.
8. Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo J, Jannatipour M and Moran RG: A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 35: 4450-4454, 1992.
9. Miles DW, Smith IE, Coleman RE, Calvert AH and Lind MJ: A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer 37: 1366-1371, 2001.
10. Dittrich C: Use of pemetrexed in breast cancer. Semin Oncol 33: S24-S28, 2006.
11. Ramalingam S and Sandler AB: Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. Oncologist 11: 655-665, 2006.
12. Kindler HL: The emerging role of pemetrexed for the treatment of malignant mesothelioma. Oncology (Williston Park) 18: 49-53, 2004.
13. Zucali PA and Giaccone G: Biology and management of malignant pleural mesothelioma. Eur J Cancer 42: 2706-2714, 2006.
14. Goedhals L, van Wiyk AL, Smith BL and Fourie SJ: Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial. Int J Gynecol Cancer 16: 1172-1178, 2006.
15. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30, 2004.
16. Miller KD, Picus J, Blanke C, John W, Clark J, Shulman LN, Thornton D, Rowinsky E and Loehrer PJ Sr: Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 11: 101-103, 2000.
17. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B and Wils JA: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18: 2648-2657, 2000.
18. Logothetis CJ, Johnson DE, Chong C, Dexeus FH, Sella A, Ogden S, Smith T, Swanson DA, Babaian RJ and Wishnow KI: Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 6: 1590-1596, 1988.
19. Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J and Schneider M: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 85: 649-655, 2001.
20. Hanauske AR, Chen V, Paoletti P and Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6: 363-373, 2001.
21. Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, Jones S, Woodworth JR, Baker S, Langley C, Mascorro D, Abrahams T and Von Hoff DD: A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44: 372-380, 1999.
22. von der Maase H, Lehmann J, Gravis G, Joensuu H, Geertsen PF, Gough J, Chen G and Kania M: A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol 17: 1533-1538, 2006.
23. Das JR, Fryar EB, Epie NN, Southerland WM and Bowen D: Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate. Anticancer Res 26: 1877-1884, 2006.
24. Fryar EB and Bowen D (dissertation advisor): The importance of sequence in combination chemotherapy: A comparison of the cytotoxic effects of selective antifolates in combination with raloxifene and 5-fluorouracil. Dissertation published in the Founders Library, Howard University, 2005.
25. Habeck LL, Mendelsohn LG, Shih C, Taylor EC, Colman PD, Gossett LS, Leitner TA, Schultz RM, Andis SL and Moran RG: Substrate specificity of mammalian folypolyglutamate synthetase for 5,10-dideazatetrahydrofolate analoge. Mol Pharmacol 48: 326-333, 1995.
26. Norbury CJ and Zhivotovsky B: DNA damage-induced apoptosis. Oncogene 23: 2797-2808, 2004.
27. Tonkinson JL, Marder P, Andis SL, Schultz RM, Gossett LS, Shih C and Mendelsohn LG: Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 39: 521-531, 1997.